About Prof. Zhao Weili
Prof. Zhao Weili is the leading lymphoma subspecialty expert in the Department of Medical Oncology at Fudan University Shanghai Cancer Center (FUSCC). A nationally recognized authority in lymphoma diagnosis and treatment, Prof. Zhao has dedicated her career to advancing precision medicine approaches for lymphoma — from accurate molecular subtyping that guides drug selection, to individualized treatment strategies for relapsed and refractory disease, to pioneering access to novel agents through clinical trials.
Prof. Zhao's clinical and research work sits at the intersection of pathology, genomics, and oncology. Her expertise in precision subtyping — using molecular profiling, gene expression analysis, and immunohistochemistry to classify lymphoma beyond conventional histology — allows her to match patients with the therapies most likely to work for their specific disease biology. This approach is particularly valuable for patients with aggressive or rare lymphoma subtypes where standard protocols may be insufficient.
Clinical Expertise
- Precision subtyping-guided treatment — molecular and genomic classification of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, T-cell lymphomas, and other subtypes to guide optimal drug selection
- Relapsed and refractory lymphoma — individualized salvage regimens for patients who have failed first-line or subsequent therapy, including CAR-T cell therapy coordination and novel agent combinations
- CAR-T cell therapy — patient selection, pre-treatment optimization, and post-CAR-T management for eligible patients with relapsed/refractory DLBCL and other B-cell lymphomas
- Clinical trials — access to novel agents and combination strategies through FUSCC's active lymphoma clinical trials program, including bispecific antibodies, ADCs (antibody-drug conjugates), and next-generation BTK inhibitors
- Hodgkin lymphoma — standard and salvage treatment including ABVD, brentuximab vedotin-based regimens, and checkpoint inhibitors (pembrolizumab, nivolumab) for relapsed disease
- Indolent lymphomas — watch-and-wait strategies, rituximab-based regimens, and lenalidomide combinations for follicular lymphoma and marginal zone lymphoma
- T-cell and NK/T-cell lymphomas — a lymphoma subtype with higher incidence in Asia; expertise in CHOP-based and L-asparaginase-containing regimens, as well as novel agents
Why Prof. Zhao Weili?
Lymphoma is not a single disease — it encompasses over 60 distinct subtypes with vastly different biology, prognosis, and treatment requirements. The difference between a correct and incorrect subtype classification can mean the difference between a curative treatment and an ineffective one. Prof. Zhao's expertise in precision subtyping ensures that patients receive a diagnosis that is not just histologically accurate but molecularly complete — providing the foundation for truly individualized therapy.
For patients with relapsed or refractory lymphoma — those who have failed standard chemotherapy and are seeking options beyond what is available at home — Prof. Zhao's access to CAR-T cell therapy and novel clinical trial agents at FUSCC represents a genuine therapeutic frontier. China has approved multiple CAR-T products for B-cell lymphoma, and FUSCC is one of the leading centers for CAR-T administration in the country.
Her leadership of FUSCC's lymphoma subspecialty program also means that patients benefit from a dedicated team with deep collective experience, rather than a general oncologist managing lymphoma as one of many tumor types.
Hospital: Fudan University Shanghai Cancer Center (FUSCC)
FUSCC is China's premier dedicated cancer hospital, affiliated with Fudan University School of Medicine. Its hematology and lymphoma program is one of the most active in China, with a dedicated lymphoma clinic, a robust clinical trials portfolio, and access to CAR-T cell therapy through both approved commercial products and investigational protocols. The hospital's pathology department — one of the strongest in China — provides the molecular and genomic testing infrastructure that underpins Prof. Zhao's precision subtyping approach.
About Lymphoma
Lymphoma is a cancer of the lymphatic system, broadly divided into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). NHL is far more common, accounting for approximately 90% of all lymphoma cases. Key facts for international patients:
- DLBCL (diffuse large B-cell lymphoma): the most common aggressive NHL; treated with R-CHOP as first-line; molecular subtyping (GCB vs. ABC/non-GCB) guides second-line strategy
- Follicular lymphoma: the most common indolent NHL; often managed with watch-and-wait for low-burden disease; rituximab-based regimens for treatment-requiring disease
- Mantle cell lymphoma: aggressive but increasingly manageable with BTK inhibitors (ibrutinib, zanubrutinib, acalabrutinib) and CAR-T for relapsed disease
- Hodgkin lymphoma: highly curable with ABVD chemotherapy; brentuximab vedotin and checkpoint inhibitors for relapsed/refractory disease
- NK/T-cell lymphoma: more common in Asia; L-asparaginase-based regimens are the cornerstone of treatment; PD-1 inhibitors show activity in relapsed disease
- CAR-T cell therapy: approved in China for relapsed/refractory DLBCL, follicular lymphoma, and mantle cell lymphoma after ≥2 prior lines; response rates of 50–70% in heavily pre-treated patients
- Bispecific antibodies (glofitamab, mosunetuzumab): emerging off-the-shelf alternatives to CAR-T with strong response rates and no need for apheresis
What to Prepare Before Your Consultation
To enable Prof. Zhao's team to conduct a thorough remote case review, international patients should prepare:
- Pathology report with full immunohistochemistry panel (CD20, CD3, CD10, BCL2, BCL6, MYC, Ki-67, and others as relevant)
- Molecular/genomic profiling results if available (cell-of-origin classification, MYC/BCL2/BCL6 rearrangements, TP53 mutation status)
- PET-CT scan (preferred for staging and response assessment) or CT of chest, abdomen, and pelvis
- Bone marrow biopsy report if performed
- LDH, beta-2 microglobulin, CBC with differential, and other relevant labs
- Summary of all prior treatment lines with regimens, dates, cycle numbers, and best response (complete/partial remission, stable disease, progression)
- Prior CAR-T or stem cell transplant records if applicable
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) coordinates access to Prof. Zhao Weili and the FUSCC lymphoma team for international patients. Our services include:
- Remote case review and pre-consultation assessment before you travel
- Priority appointment scheduling with Prof. Zhao's team at FUSCC
- Full translation of pathology reports, imaging, and treatment plans
- In-hospital accompaniment by a dedicated English-speaking case manager
- Accommodation, airport transfer, and logistics coordination in Shanghai
- Post-discharge follow-up and remote consultation support after returning home
Contact us to begin your case review:
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
0 commenti